US IRB approval of Collategene trial boosts AnGes
This article was originally published in Scrip
Shares in AnGes MG spiked in Tokyo after the Japanese bioventure announced its US subsidiary had received final institutional review board (IRB) approval for a planned pilot trial with the firm's lead therapeutic candidate.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.